Bio Products Laboratory (“BPL”), a leading manufacturer of plasma-derived protein therapies, celebrates Rare Disease Day in recognition of the critical role it plays in raising awareness for the 300 million people worldwide living with a rare disease, their families and their carers.
BPL collects plasma from its donor communities and processes it to manufacture plasma-derived therapies that are patient-focused and clinically differentiated. Some of these products are particularly relevant in treating rare diseases and targeting unmet medical needs.
BPL will be attending the International Society on Thrombosis and Haemostasis (“ISTH”) Congress in July as part of its continued engagement around rare bleeding disorders. The ISTH 2022 Congress will be held in London and is the most important international meeting of the year that offers a focus on key trends and ever evolving therapies in the field of thrombosis and haemostasis.
During the event, BPL will meet in person with health care professionals and distributors and will also provide a scientific presentation on rare disease therapies during a product theatre targeted to health care professionals.
Bob Rossilli, Chief Commercial Officer, Global Business, said, “We join Rare Disease Day in working towards equity in social opportunity, healthcare and access to diagnosis and therapies for people living with a rare disease.
“Led by UK-based specialists in plasma therapies and supported by an experienced team, we are proud to be able to apply our scientific expertise and resource to improve existing production and the development of new products, using the latest developments in medical science and clinical practice to help treat rare diseases.
“We look forward to being able to share more on this during the ISTH 2022 Congress in July.”